Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-22-080871
Filing Date
2022-07-19
Accepted
2022-07-19 17:01:01
Documents
4

Document Format Files

Seq Description Document Type Size
1 DEFA14A tm2221301d1_defa14a.htm DEFA14A 13459
2 GRAPHIC tm2221301d1_defa14aimg001.jpg GRAPHIC 4683
3 GRAPHIC tm2221301d1_defa14aimg002.jpg GRAPHIC 2127
4 GRAPHIC tm2221301d1_defa14aimg003.jpg GRAPHIC 32370
  Complete submission text file 0001104659-22-080871.txt   69183
Mailing Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807
Business Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

IRS No.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38356 | Film No.: 221092094
SIC: 2834 Pharmaceutical Preparations